Redbiotec, a Swiss biotechnology company, develops immunotherapies against Herpes and cancer.
Our therapies are based on best-in-class proteins and microorganisms.
Track record of Redbiotec in novel proteins:
- Deals closed with pharma companies in U.S., Asia and Europe
- Trade sale of spin-off Redvax to Pfizer (press release) for its CMV vaccine program
- Internationally recognized scientists as scientific advisors
- Engineering and production of >100 novel proteins and protein complexes
- First company having successfully developed stable CMV pentamer at >95% purity
Growing traction and growing team for Redbiotec’s oncology program
Big and growing interest in Redbiotec's COMOS and in Redbiotec's engineered bacteria carrying CRISPR. Redbiotec therefore further invests in its promising IO platforms.
Large portfolio of novel bacteria to fight cancer
Redbiotec is currently engineering and producing a number of novel bacteria strains to fight cancer.
The Summit summit – World record holder Dani Arnold for fastest Matterhorn climb boosting Redbiotec
Dani Arnold, one of world's top mountaineers and climbers, world speed record holder of Matterhorn North Face joins Redbiotec.